ORDER & REASONS
Before the Court are three motions: (1) defendants Shell Oil Company and Shell Chemical Company’s (collectively “Shell”) Motion to Dismiss Pursuant to Rule 12(b)(6) (R. Doc. 18); (2) Shell’s Motion to Strike Pursuant to Rule 12(f) (R. Doc. 19); and (3) defendants Travelers Insurance Company and The Travelers Indemnity Company’s (collectively “Travelers”) Motion to Apply the Court’s Ruling on the Motion to Dismiss and Motion to Strike to Travelers (R. Doc. 22). For the following reasons, Shell’s Motion to Dismiss is GRANTED IN PART and DENIED IN PART; Shell’s Motion to Strike is GRANTED IN PART and DENIED IN PART; and Travelers’ Motion is GRANTED.
I. BACKGROUND
This case arises from the illness and death of a spouse allegedly resulting from exposure to benzene in his workplace. The decedent spouse, Welman Frank, worked at the Shell Norco refinery from
During his employment at the Norco refinery, it is alleged that Mr. Frank was exposed to unsafe levels of benzene on a daily basis related to Shell’s role as a manufacturer and seller of benzene or benzene-containing products. It is further alleged that this exposure to benzene resulted in Mr. Frank’s development of Acute Lymphoblastic Leukemia (“ALL Leukemia”). Mr. Frank was diagnosed with ALL Leukemia in 2002, and died that same year.
On April 15, 2011, the surviving spouse of Mr. Frank, Plaintiff Lois Frank, filed suit in this Court, individually and on behalf of her husband against defendants Shell and Travelers. (R. Doc. 1). Plaintiff alleges her husband’s significant exposure to benzene and/or benzene-containing products was the result of the acts or omissions of Shell and Shell’s deceased executive officers, and such acts or omissions were a substantial, contributing cause in the development of Mr. Frank’s ALL Leukemia. Plaintiff further alleges Shell knew its employees were developing blood disorders and cancers at the Norco facility and conducted internal medical studies to verify these and other health hazards related to their benzene products. Plaintiff brings the following claims against the defendants: fraudulent concealment, negligence, strict products liability, former Article 2317 liability, concealment, misrepresentation, fraud, unjust enrichment, loss of consortium, loss of services, loss of affection, loss of nurture, and intentional tort. Plaintiff seeks both compensatory and exemplary damages. She also has requested trial by jury.
II. SHELL’S MOTION TO DISMISS
A. Summary of Memoranda
1. Shell’s Motion
Shell filed a Motion to Dismiss Pursuant to Rule 12(b)(6). (R. Doc. 18). Shell raises two bases for its Motion: (1) Plaintiffs claims are prescribed on the face of the Complaint, and (2) Plaintiffs claims are barred by the exclusive remedy provision of the Louisiana Workers’ Compensation Act (“LWCA”).
Turning first the prescription argument, Shell alleges that Plaintiffs claims are prescribed on the face of the Complaint because the claims prescribed one-year from the death of the decedent in 2002, yet Plaintiff did not file suit until 2011. Because these claims are prescribed facially, Shell contends Plaintiff bears a heavy burden of establishing this prescription has been suspended or interrupted and fails to carry this burden because there was constructive knowledge of the claims well before the year preceding the Complaint. Next, Shell alleges the one-year limitations period for Plaintiffs survival action is peremptive and cannot be interrupted or suspended.
With regard to Shell’s LWCA argument, it alleges that Plaintiffs claims are barred by the exclusive remedy provision because the intentional act exception is inapplicable.
2. Plaintiffs Response
Plaintiff filed a Response in opposition to Shell’s Motion. (R. Doc. 21). Plaintiff claims that prescription statutes are to be strictly construed against prescription, with the burden on Shell as the party raising the prescription issue. Plaintiff further claims that prescription was pre
With regard to Shell’s claims involving the LWCA, Plaintiff notes Mr. Frank was contract worker, and not an employee, of Shell from 1972-73, and thus, the LWCA does not apply to that time period. Further, Plaintiff claims that because Mr. Frank was an employee of Shell prior to the revision of LWCA which grants immunity to executive officers, Shell is liable in tort for the actions and omissions of its executive officers. Finally, Plaintiff argues that the LWCA does not apply to her claims because they fall within the intentional tort exception to the Act.
3. Shell’s Reply
Shell filed a Reply in further support of its Motion. (R. Doc. 33). Shell reiterates its prior argument that Plaintiffs claims are time-barred because Mr. Frank was diagnosed with cancer and died in 2002, more than eight years before the present suit was filed. Shell claims that the Complaint acknowledges the dangers of benzene exposure were publicly known and available since 1977. Shell also contends that Plaintiff fails to make any specific fraud claims which could toll the running of prescription.
With regard to the application of the LWCA, Shell argues that the intentional tort exception does not apply because the intentional tort allegations in Plaintiffs complaint are merely conclusory, and there exists no case law holding that exposure to benzene constitutes an intentional tort.
B. Law & Analysis
1. Standard of Review
When a court considers a motion to dismiss for failure to state a claim under Federal Rule of Civil Procedure 12(b)(6), “all well-pleaded facts are viewed in the light most favorable to the plaintiff, but plaintiffs must allege facts that support the elements of the cause of action in order to make out a valid claim.” City of Clinton v. Pilgrim’s Pride Corp.,
2. Prescription
As a threshold matter, the Court recognizes that “Louisiana law controls ... a federal court sitting in diversity will apply state prescription periods as substantive law.” Ricard v. Essex Ins. Co.,
As noted above, the Complaint alleges the following claims on behalf of Plaintiff and her deceased husband: fraudulent
“[Prescription statutes are strictly construed against prescription and in favor of the obligation sought to be extinguished; thus, of two possible constructions, that which favors maintaining, as opposed to barring, an action should be adopted.” Carter v. Haygood, 2004-0646, p. 10 (La.1/19/05),
Plaintiff seeks to satisfy this burden by arguing the doctrine of contra non valentem prevented the running of prescription on her claims. Plaintiff includes in her Complaint allegations aimed at protecting her from a prescription attack. These allegations state,
The prescriptive period does not start until the plaintiffs knew or should have known that the plaintiffs ALL Leukemia was caused by benzene. Here, the result of the plaintiffs [sic] exposure to benzene was inherently undiseoverable. The cancer took years to develop, and even when the symptoms did manifest, neither the physicians nor the plaintiffs detected the link between his benzene exposures and his malignancies. The [sic] Welman Frank never heard or saw anything that linked benzene to his malignancy. Mrs. Frank, Welman Franks [sic] widow, did not learn of a possible connection between the benzene Mr. Frank was exposed [to] and his illness until February of 2011. Mr. Frank’s cancer was the product of exposure to these chemicals over a period of time rather than form [sic] a single point in time. Hence, the limitation period didn’t start until earlier this year when the plaintiff learned about the cause of his Leukemia. (R. Doc. 1).
Hnder Louisiana law, “[t]o soften the occasional harshness of prescriptive statutes, our courts have recognized a jurisprudential exception to prescription: contra non valenteum non currit praescriptio, which means that prescription does not run against a person who could not bring his suit.” Carter, 2004-0646 at p. 11,
Turning to the first of Plaintiffs arguments, the Louisiana Supreme Court has characterized this type of contra non valentem as “implicated only when, (1) the defendant engages in conduct which rises to the level of concealment, misrepresentation, fraud, or ill practice; (2) the defendant’s actions effectually prevented the plaintiff from pursuing a cause of action; and (3) the plaintiff must have been reasonable in his or her inaction.” Marin v. Exxon Mobil Corp., 2009-2368, p. 24 (La.10/19/10),
In support of this first type of contra non valentem, Plaintiff alleges Shell fraudulently concealed the dangers of benzene, Shell failed to inform decedent of the dangers and health risks associated with benzene, and Shell failed to train its workers on the health risks of benzene. In response, Shell contends that because prescription is not tolled when a Plaintiff could have learned of the cause of his injuries through reasonable diligence, Plaintiff defeats her own argument by including in the Complaint allegations stating that the health hazards associated with benzene exposure have been recognized for over 100 years and this information has been publicly available and accessible. Additionally, Shell claims Plaintiffs allegations against it do not rise to the level of fraud required for this type of contra non valentem to apply.
Plaintiff does not sustain her burden of demonstrating the applicability of this type of contra non valentem because she has not alleged Shell “effectually prevented” her from pursuing her claims. See Marin, 2009-2368 at p. 24,
“Louisiana courts have used the doctrine of contra non valentem to suspend the running of prescription when the cause of action is not known or reasonably knowable by the plaintiff, even though his ignorance is not induced by the defendant.” Bartucci
In the Complaint, Plaintiff alleges that Mr. Frank’s “cancer took years to develop, and even when the symptoms did manifest, neither the physicians nor the plaintiffs detected the link between his benzene exposures and his malignancies. The [sic] Welman Frank never heard or saw anything that linked benzene to his malignancy____until February of 2011.” (R. Doc. 1). Taking these statements as true, as must be done in a Rule 12(b)(6) motion, the Court finds these allegations are sufficient to demonstrate the applicability of contra non valentem to suspend the running of prescription until February 2011
Shell challenges the application of the discovery rule, arguing Plaintiff had con
The health hazards of benzene have been recognized for over 100 years. Benzene has been medically recognized as a carcinogen known to cause leukemia, and other blood diseases for decades. By the end of 1948 it was widely known in the United States, to those in defendants’ industry, as well as the named Defendants that exposure to benzene could cause a myriad of ill health effects including such diseases as leukemia and other blood disorders. Through internal medical studies unknown to plaintiffs, the defendants knew of the health hazards inherent in the products they manufactured, distributed, sold, supplied, owned, transported, or used.
The causal connection between injuries such as leukemia and benzene has been scientifically documented since the early 1900’s. (R. Doc. l)(emphasis added).
Shell’s argument ignores critical language in these allegations, particularly that stating the benzene danger was well-known to Shell and others in similar industries, and that this danger was scientifically and medically recognized, but not in studies of which Plaintiff was aware. See id. (noting emphasized language above).
Whether it was unreasonable for Plaintiff to be unaware of this information before the expiration of prescriptive is based upon a number of factors. Here, there are no allegations that Plaintiff had access to or actually received the studies and information recognizing the cancer-causing propensity of benzene. See Cross v. Alpha Therapeutic Co.,
Shell also argues that Plaintiffs survival action claims are peremptive and thus cannot be interrupted or suspended under contra non valentem. While there exists jurisprudence supporting this argument, such predates or relies on precedent predating the amendment of the survival action provision in Louisiana Civil Code article 2315.1. See e.g. Ayo v. Johns-Manville Sales Corp.,
S. Workers’ Compensation
Shell also seeks dismissal of Plaintiffs claims on the basis that they are barred by the exclusive remedy provision of the Louisiana Workers’ Compensation Act (“LWCA”). It contends the intentional act exception to the LWCA does not apply to Plaintiffs claims. In response, Plaintiff argues that the older version of the LWCA applies to her claims because the events giving rise thereto occurred prior to the 1976 revisions, and the pre-1976 version does not grant immunity to executive officers. She also alleges the intentional tort exception to the LWCA does apply.
As a general matter, the LWCA provides the exclusive remedy to an employee for injury, sickness, or disease arising during the course and scope of employment. See La.Rev.Stat. § 23:1032(A). Plaintiff does not dispute Mr. Frank’s alleged benzene exposure and later diagnosis of and death from ALL Leukemia constitute covered injury, sickness, or disease under the LWCA.
Plaintiff argues her claims arising from Mr. Frank’s time at the Norco refinery from 1972-1973 as a contract worker are not governed by the LWCA because Mr. Frank was not a statutory employee of Shell. In response, Shell argues Mr. Frank would have been a statutory employee under the version of the LWCA in effect during his contract work, and thus, the claims arising from this time period are barred by the LWCA. The Court agrees with Shell that the LWCA in effect at the time of Mr. Frank’s work determines his employment status. See Emery v. Owens-Corp., 2000-2144, p. 6 (La.App. 1 Cir. 11/9/01),
‘That where any person (in this section referred to as principal) undertakes to execute any work, which is a part of his trade, business or occupation or which he had contracted to perform, and contracts with any person (in this section referred to as a contractor) for the execution by or under the contract of the whole or any part of the work undertaken by the principal, the principal shall be liable to pay to any employee employed in the execution of the work or his dependant any compensation under this act which he would have been liable to pay if that employee had been immediately employed by him.’ Thibodaux v. Sun Oil Co.,218 La. 453 ,49 So.2d 852 , 853 (La.1950)(citing LWCA provision regarding its application to employees of independent contractors, current Louisiana Revised Statute 23:1061).
Here, Plaintiff alleges “Mr. Frank worked as a contract worker at the Shell Norco refinery from 1972 to 1973. He was tasked with cleaning out storage tanks.” (R. Doc. 1). She also alleges Mr. Frank conducted the same task of cleaning tanks when he became an employee of Shell. See id. This indicates that as both a contract worker and an employee at Shell, Mr. Frank was doing work which was part of the “trade, business or occupation of the principal.” See e.g. Thibodaux,
Since the LWCA came into existence, particularly during the course of Mr. Frank’s employment at the Norco refinery, the Act has undergone several significant changes. Thus, as a threshold matter, the question of which version or versions of the LWCA apply to Plaintiffs claims must be resolved. This is particularly important here for determining, (1) whether Plaintiff can pursue her tort claims against Shell’s executive officers, and (2) whether the intentional tort exception applies to Plaintiffs tort claims, see Bazley v. Tortorich,
It is well settled that the LWCA generally applies as the exclusive remedy for both wrongful death and survival actions filed by the survivors of an injured worker, the very claims at issue here. See Deshotel v. Guichard Operating Co., Inc.,
With regard to Plaintiffs wrongful death claims, the Louisiana Supreme Court has held that the LWCA in effect during the time of death is applicable. See Walls v. Am. Optical Corp., 98-0455 (La.9/8/99),
With regard to the Plaintiffs survival action claims, the applicable law is
Plaintiff alleges Mr. Frank was exposed to benzene while working at Shell from 1972 to 2002. (R. Doc. 1). The LWCA in effect from 1972 to 1975 excepted from coverage claims against executive officers, but with the 1976 amendments executive officers were treated the same as employers covered by the Act. See Bazley,
In 1976 the Louisiana Legislature codified an exception to the exclusivity provisions of the LWCA for when the employee’s injury or disease is caused by an intentional tort. See La.Rev.Stat. § 23:1032(A); Zimko v. Am. Cyanamid,
In the context of the LWCA, the Louisiana Supreme Court defines an intentional tort as occurring when “the person who acts either (1) consciously desires the physical result of his act, whatever the likelihood of that result happening from his conduct; or (2) knows that the result is substantially certain to follow from his conduct, whatever his desire may be as to that result.” Bazley,
Under the substantially certain exception, the jurisprudence requires more than a reasonable probability that an injury will occur and defines “certain” to mean “inevitable” or “incapable of failing.” Zimko, 2003-0658, at p. 12,
Here, the Complaint alleges in the “Intentional Tort” section,
Shell was well aware of the serious health hazards associated with the use of benzene. Consequently, if companies such as Shell had concern for the health and well-being of workers using and/or being exposed to benzene and benzene-containing products, they should have provided information and warnings on the need to limit exposures, educated workers, measured airborne exposure levels, provided adequate and safely designed protective equipment, and conducted medical examinations.
The actions and inactions of the [sic] Shell and its executive officers, whether taken separately, or together, were of such character as to constitute a patternor practice of intentional wrongful conduct and/or malice resulting in damage and injury to the Plaintiffs. More specifically, Shell and its executive officers, consciously and/or deliberately engaged in oppression, fraud, wantonness and/or malice with regard to Welman Frank and other employees. Therefore, Shell should be held liable for the intentional infliction of physical injury upon its employee, Mr. Welman Frank. (R. Doc. 1).
In a later section of the Complaint, entitled “Shell Benzene Industrial Hygiene” Plaintiff appears to add further intentional tort allegations, including,
Shell intentionally exposed Mr. Frank to benzene and benzene-containing products by the conditions .of work it imposed upon him. Shell actually knew that he [sic] conditions of work would cause exposure to benzene and benzene-containing products, and that such exposure would cause injury. Exposure to benzene and benzene-containing products is a harmful or offensive bodily contact. Shell knowingly and intentionally exposed Mr. Frank to benzene and benzene-containing products that caused injury. Mr. Frank’s exposure lead directly to the development of ALL Leukemia. Therefore, [Shell] intentionally exposed Welman Frank to benzene and benzene containing products with the knowledge that such exposure was substantially certain to cause serious injury to Mr. Frank including damage to his blood.
Shell knew within a substantial certainty that the conditions of work which it imposed upon Mr. Frank and over which it had total control, would result in offensive touching, offensive contact and exposure to benzene and benzene-containing products. For many years, the [sic] Shell actually knew that exposure to benzene and benzene-containing products could naturally, directly and probably result in the disease of ALL Leukemia in a person who received exposure or offensive touching and contact. However, Shell intentionally chose to continue its course of conduct and allowed workers such as Mr. Frank to be exposed to benzene and benzene-containing products.
The above conduct, as well as other conduct on the part of (sic) the Shell, constitutes outrageous conduct and conduct which Shell knew to a substantial certainty would cause exposure to benzene and benzene-containing products from which all manner of damages would flow, including, but not limited to:
a. Benzene and benzene-containing products-related disease;
b. Leukemia, blood disorders, other related conditions, resulting pain, suffering and mental anguish;
c. Emotional distress. (R. Doc. 1).
Plaintiff also alleges, based upon exhibits to her Complaint, that Shell prepared memoranda regarding and had reported knowledge that exposure to benzene causes blood diseases and disorders and certain cancers, but that Shell concealed such information. See (R. Doc. 21).
Based upon the foregoing, Plaintiff has not sufficiently alleged intentional tortious behavior on the part of Shell to prevent dismissal of her post-1975 claims. These allegations do not demonstrate Shell was “substantially certain” Mr. Frank would be diagnosed with ALL Leukemia due to his exposure to benzene and benzene-related substances, but rather indicate that Shell “knowingly permitted] a hazardous work condition to exist, knowingly order[ed] claimant to perform an extremely dangerous job, or willfully fail[ed] to furnish a safe place to work,” all of which the Louisiana Supreme Court holds is insufficient for an intentional tort. See
The cases relied upon by Plaintiff to support her intentional tort argument are all factually distinguishable from the present case. For example, in Swope v. Columbian Chemicals Co.,
Shell filed a Motion to Strike, seeking an order from the Court striking from the Complaint a number of allegations and supporting exhibits. (R. Docs. 19, 31). Plaintiff opposes Shell’s Motion. (R. Doc. 20).
A. Law & Analysis
1. Motion to Strike
A motion to strike filed pursuant to Federal Rule of Civil Procedure 12(f) provides that a “court may strike from a pleading an insufficient defense or any redundant, immaterial, impertinent, or scandalous matter.” Fed.R.Civ.P. 12(f). The decision to grant or deny a motion to strike lies within the sound discretion of the trial court. Admin’rs of the Tulane Educ. Fund v. Biomeasure, Inc.,
2. Analysis
Shell raises nine arguments in support of its Motion. The Court will summarize each of these arguments in turn, Plaintiffs responses thereto, and issue rulings based upon the relevant facts and applicable law.
a. Dr. Joyner’s Deposition Testimony
First, Shell argues the allegations referencing the deposition testimony of Dr. Roy Joyner in the Bishop litigation should be stricken because they mischaracterize the substance and source of Dr. Joyner’s testimony, are prejudicial and scandalous, and have no bearing on the issues raised in the present litigation. In response, Plaintiff argues these allegations and supporting testimony are relevant to her fraudulent concealment, contra non valentum, failure to warn, and intentional tort claims.
The allegations in the Complaint at issue provide,
42. On August 01,1977, Dr. Joyner and Dr. Stallones testified under oath that Shell did not have any other cases of blood dyscrasia other than the leukemia cases presented to OSHA.
43. Shell failed [sic] disclose the 8 cases of multiple myeloma, and the 18 cases of lymphoma to OSHA at the Temporary Benzene Standard Hearings. (R. Doc. 1).
Plaintiff directs the Courtis attention to previously unreferenced portions of Dr. Joyner’s deposition, particularly the section in which the questioning attorney appears to be reading Dr. Joyner’s testimony from the 1977 OSHA hearing. This section provides, “Ms. Murray, question, “Were there any other deaths attributable to blood dyscrasias?’ First, Dr. Stallones says, ‘There certainly were. The particular focus was on leukemia, and I did not have any great detail on the other causes of death.’” Id. at 34:16-21. This fails to support the allegations in the Complaint. For one, Dr. Joyner did not testify in the 2009 deposition as to what he or Dr. Stallones said at the 1977 OSHA hearing, rather the questioning counsel allegedly read from the transcript of the hearing. This constitutes hearsay, is unauthenticated, and cannot be attributed to testimony of either Dr. Joyner or Dr. Stallones. Further, the condition of which Mr. Frank died was ALL Leukemia so it is immaterial to the present litigation even if there existed other undisclosed causes of death.
Plaintiff also cites to other areas of Dr. Joyner’s deposition testimony, claiming such demonstrates Shell withheld information regarding employees developing leukemia and other conditions. However, upon review of this testimony, Dr. Joyner does not recollect whether Shell had non-leukemia cases of blood dyscrasia and testifies only leukemia information was sent to OSHA because it was requested. See id. The only evidence of the 8 cases of multiple myloma and 18 cases of lymphoma allegedly withheld is contained in a study read into the record by the questioning attorney. See id. If this study is the basis of Plaintiffs allegations, it should be attached to the Complaint, because as it stands now it constitutes hearsay and unauthenticated evidence.
Plaintiff also cites to a letter from the U.S. Department of Labor, Occupational Safety and Health Administration, to Shell’s Manager of Product Safety and Compliance on December 22, 1982, containing information regarding employee deaths attributable to leukemia, among other causes. See (R. Doc. 1-13). A letter written by OSHA to Shell in 1982 would have no bearing on the testimony at the 1977 OSHA hearing.
Based upon the foregoing, the Court finds paragraphs 42 and 43 of the Complaint are to be stricken. These allegations mischaracterize the supporting evidence and are prejudicial to Shell. They are also immaterial since they involve failure to disclose conditions and diseases which are not at issue in the present litigation.
b. Medical Surveillance Database
Second, Shell argues that Exhibit 1, entitled “Shell Oil Co. Medical Surveillance Database for Multiple Myeloma” and references to this exhibit should be strick
The specific allegations at issue provide,
13. The Defendants knew that Shell employees were developing blood disorders and cancers at the Norco, Louisiana facility prior to 1960. Shell failed to warn its’ [sic] workers that Shell employees were contracting AML, ALL, CLL, CLM and other forms of leukemia; aplastic anemia; myelodysplastic syndrome; lymphoma, and other one hundred and fifty (150) cases of multiple myeloma from 1960 through 2009.
38. In 1961, Shell Oil Co. documented the first employee case of multiple myeloma.
54. Shell documents released in 2009 show that Shell employees with 20-29 years of service include 45 cases of multiple myeloma; and employees with 30-39 years of service include 67 cases of multiple myeloma.
55. Shell documents released in 2009 list the deaths of Shell Oil employees from multiple myeloma in 2009 as follows: 37 deaths of Shell employees in the 1980’s; 45 deaths of Shell employees in the 1990’s and 49 deaths of Shell employees from 2000 through 2009. These documents show one hundred and fifty (150) deaths of Shell employees from multiple myeloma from 1961 through 2009 which included statistically significant excesses for many of the years.
56. Shell [sic] date produced in 2009 documents employee deaths from multiple myeloma as follows: 24 cases at Deer Park, 5 cases at Martinez, 6 cases at Norco, 11 cases at Wood River, and 104 cases at other Shell facilities. (R. Doc. 1).
Each of these allegations cites to Exhibit 1 to the Complaint which is entitled “The FREQ Procedure.” It is Bates numbered for the 2009 Bishop litigation and contains a series of charts. It contains no mention of Shell, benzene, ALL Leukemia, or multiple myeloma. Without further authentication or explanation, the Court is unable to confirm that the data in Exhibit 1 supports the subject allegations. Further, these allegations largely pertain to multiple myeloma, which was at issue in the Bishop litigation, but is not here. Accordingly, these allegations are stricken as both prejudicial to Shell and immaterial to the present litigation. However, at this juncture the Court makes no ruling as to the admissibility of Exhibit 1 at trial since a decision on this issue is premature.
c. C.H. Hines Letter
Third, Shell argues paragraph 37 and Exhibit 4, a letter from C.H. Hines on Shell letterhead, should be stricken because they mischaracterize the content of Exhibit 4 which states benzol will not cause cancer and no medical opinions exist connecting benzene with leukemia. In response, Plaintiff argues she did not mischaracterize the substance of Exhibit 4 and that Shell’s argument fails because she is only required to plead a short and plain statement of the claims. She claims Exhibit 4 demonstrates Shell knew about the dangers of benzene but refused to acknowledge or inform its employees of
Paragraph 37 of the Complaint states, “[i]n 1957, CH Hines reported that Shell Oil Co., has known for years that benzene causes damage to the blood. Yet, by 1957 Shell was not informing workers of the health hazards and dangers of benzene.” (R. Doc. 1). Only the first sentence cites to Exhibit 4, which is a letter dated January 22, 1957, from C.H. Hiñe, M.D., PhJD, Consultant on Occupational Health & Industrial Toxicology for the Shell Development Company, to Mr. G.W. Waters of Shell Oil Company. See (R. Doc. 1-6). Therein, Dr. Hine states “[i]t has been known for many years that benzol will cause a reduction in the number of red and white cells and some reduction of the lymph tissues. However, these findings are reversible and are not of a malignant or cancerous type.” Id. The letter also acknowledges “the suggested connection between benzol exposure and leukemia” in reports/literature, but discounts such as lacking evidence. See id. The Court finds that paragraph 37 is properly based upon the letter from Dr. Hines and does not contain prejudice or immateriality. Thus, the Court declines to strike either under Rule 12.
d. Internal Training Manual
Fourth, Shell argues the allegations in paragraph 46 and portion of Exhibit 10 should be stricken because, contrary to Plaintiffs description, there is no “internal training manual” in Exhibit 10, but rather the document at issue was authored by a company called Envirohealth, Inc., and there is no evidence Shell knew about or used this document. In response, Plaintiff argues the document is clearly labeled as a Shell document and was sent to numerous Shell staff. According to Plaintiff, attached to this document is a study reporting a higher incidence of certain leukemia in refinery workers. Shell filed a Reply brief clarifying it is not objecting to the characterization of the documents in pages 1-2 of Exhibit 10, but rather it is objecting to the attribution of pages 13-21, the Envirohealth, Inc. report, as a Shell training manual and the imputation of any statements in those pages to Shell.
Paragraph 46 states “[i]n 1981, Shell Oil Co. circulated a memo stating that statistically significant increases in multiple myeloma and Lymphoblastic leukemia were found in a study, and an internal training manual says benzene causes multiple myeloma and leukemia [sic] Shell failed to inform it [sic] worker’s [sic] including Mr. Frank of the findings.” (R. Doc. 1). Shell does not dispute the first clause of this allegation; nor does the Court find a basis therefore since the internal Shell memo does state “statistically significant increases in cancer incidence were observed for lymphocystie leukemia in refinery workers, multiple myeloma in petrochemical workers, and melanoma in those plants reporting from the middle Atlantic Region. Nonlymphoeystic leukemia, especially granulacystic or myelogenous leukemia was not increased to statistically significant levels: It is this latter form of leukemia which is sometimes implicated in benzene exposure.” (R. Doc. 1-12).
With regard to the second clause of paragraph 46, Plaintiff characterizes a second attachment to the Shell internal memo, which is not referenced in the memo, as an “internal training memo” presumably because of a hand-written note on the front of the document stating “respiratory training (keep per eip.; > 75 yrs.)” See id. at p. 13. However, as Shell notes there is not indication that this report, authored by “Envirohealth, Inc.,” was a Shell document or used by Shell to train
e. Tsai Deposition Testimony
Fifth, Shell argues paragraphs 63-65 referencing the deposition testimony of Shan Tsai, Ph.D. from the Bishop litigation found in Exhibit 18 should be stricken because Plaintiffs allegations mischaracterize this testimony which only involves multiple myeloma, rending it immaterial to the present claims and prejudicial to Shell. In response, Plaintiff argues her allegations should not be stricken because Dr. Tsai testified that the mortality/medical surveillance records were from Shell’s own database and that Shell failed to disclose injuries and deaths in its study to the EPA.
The allegations at issue state,
63. Dr. Shan Tsai, Manager of Epidemiology for Shell Oil Co. testified that he began working in the Epidemiology Department at Shell Oil in 1988. Dr. Tsai testified that Shell Oil has not conducted a single study of Shell employees that died of multiple myeloma. Shell failed to conduct a study of employees that developed ALL Leukemia.
64. Dr. Tsai testified that Shell has never attempted to calculate the incidence rate for the 150 deaths of multiple myeloma.
65. Dr. Tsai testified that the Shell Oil Epidemiology Department does not reports cases of multiple myeloma to the USEPA under the Toxic Substance Control Act. (R. Doc. 1).
To the extent these allegations pertain to multiple myeloma, the Court finds they should be stricken since multiple myeloma is not involved in the present matter and references thereto may prejudice Shell. Further, because Dr. Tsai’s testimony is void of any mention of ALL Leukemia to the extent Plaintiff attributes the ALL Leukemia allegation to the testimony of Dr. Tsai, such should be stricken as well.
f Litigation Strategy Documents
Sixth, Shell argues paragraph 69 and Exhibit 26 should be stricken because the “Shell litigation strategy documents” upon which these items are based are undated and unauthenticated and contain an express disclaimer that the contents thereof do not represent the views of Shell. In response, Plaintiff argues the litigation strategy documents are relevant because they are evidence of Shell’s strategies to confuse, obfuscate, and mislead courts and juries as to the truth of benzene.
Paragraph 69 provides
In a final example of the pattern of fraudulent concealment that has been ongoing for decades, Shell litigation strategy documents calls [sic] for concealing sensitive documents and leaves the reader with a poem to further instruct counsel to confuse the trier of fact on the relationship between blood cancers and diseases as follows: ‘SMOKE SCREEN’ ‘One fine morning in the middle of the night Two dead boys got up to fight. Back-to-back they faced each other, Drew their swords and shot each other, A deaf policeman heard the noise And came and shot the two dead boys. If you don’t believe my tale is true, Ask the blind man, he saw it too.’ (R. Doc. 1).
Exhibit 26 from which this allegation quotes is a document by Richard G. Faulk entitled “Benzene Litigation: Duties, Defenses and Strategies.” (R. Doc. 1-28). The documents also states that Mr. Faulk is the senior litigation attorney for Shell,
g. Affidavit of Frank M. Parker, III
Seventh, Shell argues paragraph 99 and Exhibit 20, the affidavit of Frank M. Parker, III, upon which this paragraph relies, should be stricken because they are not based upon personal knowledge, and contain irrelevant and immaterial information and improper legal conclusions. Specifically, Shell complains Mr. Parker lacks personal knowledge because he has never been to the Shell Norco facility and his testimony involves pipefitting which is not at issue in the present matter. In response, Plaintiff argues Mr. Parker, as a high-level industrial hygienist for Shell, had personal knowledge of Shell’s health and safety practices.
Paragraph 99 provides,
Frank Parker, III, former manager of Shell Oil Co.’s Industrial Hygiene Program testified that: 1) Shell did not have a [sic] industrial hygienist stationed in Norco until the late 1970’s’; 2) Shell resisted the 1977 benzene standard; 3) Shell Norco had inadequate resources to protect workers at Norco from Benzene exposure; 4) Shell failed to evaluate the risks at Norco to protect the workers from benzene exposure; 5) Shell did provide personal protective equipment to protect workers from benzene exposure3 ; 6) economic and management decisions resulted in exposure of workers to benzene at Norco; 7) Shell made a decision not to warn workers of benzene exposure dangers in the 1970’s; 8) pipefitters at Shell Norco were exposed to benzene vapors on a regular and frequent basis; 9) Shell knew that pipfitters [sic] were regularly exposed to unsafe levels of benzene exposure at Norco; 10) Shell failed to warn pipefitters of the dangers of benzene; and 11) Shell knew of the health hazards associated with benzene exposure including aplastic anemia and leukemia prior to the 1970’s. (R. Doc. 1).
Exhibit 20, Mr. Parker’s affidavit, supports the allegations in paragraph 99. See (R. Doc. 1-22). Given Mr. Parker’s role at Shell as the Director of the Corporate Industrial Hygiene Laboratory, the Court finds he would likely have personal knowledge of the health and safety practices of the Shell Norco facility, including with regard to benzene. See id. However, the Court finds the allegations regarding pipe-fitters at Norco to be immaterial to the present litigation since there is no allegation Mr. Frank was a pipefitter at Shell; thus sub-allegations 8, 9, and 10 are to be stricken from the Complaint. The Court will not for purposes of the present Motion determine the ultimate admissibility of the affidavit, though certain of the legal conclusions therein are questionable.
h. Draft Report
Eighth, Shell argues Exhibit 25, “December 1978, Draft Report: Human and Animal Toxicology of Benzene,” should be stricken because it “is not identified, referenced, or cited anywhere in the Complaint.” Plaintiff does not address Exhibit 25 in its Response. The Court also is unable to locate a reference or citation to this document in the Complaint. While
i. Unattributed Quotations
Ninth, Shell argues that paragraphs 31 and 32 of the Complaint should be stricken because they are merely unattributed quotations from Exhibit 2, a 1948 article from the American Petroleum Institute Toxicological Review, without explanation as to their application to the claims in the litigation. In response, Plaintiff argues these allegations and exhibit are relevant because Shell was a member of the American Petroleum Institute and would have received this report, supporting her claims that Shell knew about the causal relationship between benzene and cancer-related illness.
It is concerning that Plaintiff fails to attribute the allegations in paragraphs 31 and 32 to the article in Exhibit 2, especially since much of the language is directly quoted. Aside from this, the Court finds paragraphs 31 and 32 should be stricken because they fail to indicate how they are related to the present matter. Accordingly, the Court strikes paragraphs 31 and 32, but does not make any ruling at this time as to the admissibility of the actual article to which these paragraphs should have been attributed.
IV. TRAVELER’S MOTION TO APPLY THE COURT’S RULING
Travelers filed a Motion to Apply the Court’s Ruling on the Motion to Dismiss Pursuant to Rule 12(b)(6) and Motion to Strike Pursuant to Rule 12(f) filed by Shell to Travelers (R. Doc. 22). Travelers notes it was sued by Plaintiff pursuant to the Louisiana Direct Action Statute as the alleged liability insurer of Shell and Shell’s alleged executive officers. According to Travelers, because there are no independent claims against it and its liability is solely derivative of the liability of Shell, it is entitled to the same relief afforded to Shell.
Plaintiff filed a Response in opposition, incorporating many of its arguments raised in the other motions addressed in this Order & Reasons and arguing she has independent claims against Travelers “based on executive officer liability and the Louisiana Direct Action Statute, in addition to any liability the [sic] would fact [sic] under their insurance policies for intentional torts by the Executive Officers.” (R. Doc. 25). She further argues, “[a]s the insurer of the executive officers, even if the court finds that Shell was protected by the Louisiana Worker’s Compensation Laws, this would not relieve Traveler’s [sic] from liability for the act of Shell’s executive officer from the time period of 1972 to 1976.” Id.
Plaintiff has filed claims against Travelers under Louisiana’s direct action statute, alleging Travelers provided insurance coverage to Shell and Shell’s executive officers from 1972 to 1978. See (R. Doc. 1). “When an insurance company issues a policy of insurance to an employer covering claims for injuries to employees that may arise within the scope of the employer’s business ... during the period such insurance is in effect, claims for injuries occurring during such period by such employees against the employer or the insurance company shall be exclusively under the workers’ compensation act.” La. Rev.Stat. 23:1166. Thus, the claims against and liabilities of an employer for injuries to its employees are coextensive with that of its liability insurer. See Kelley v. M & M Dodge, Inc.,
V. CONCLUSION
For the foregoing reasons, Shell’s Motion to Dismiss is GRANTED IN PART and DENIED IN PART; Shell’s Motion to Strike is GRANTED IN PART and DENIED IN PART; and Travelers’ Motion is GRANTED, as specified by the Court.
Notes
. Plaintiff alleges in her Response brief that she learned in February 2010 Mr. Frank's illness and death could have been caused by his exposure to benzene at the Shell Norco refinery. See (R. Doc. 21, p. 2). If true, this would render Plaintiffs claims prescribed even under the discovery rule of contra non valentem. The Court will assume for purposes of the present Motion this was a typographical error.
. Under the current version of the LWCA, a covered occupational disease is defined as a “disease or illness which is due to causes and conditions characteristic of and peculiar to the particular trade, occupation, process, and employment in which the employee is exposed to such disease.” La.Rev.Stat. § 23:1031.1(A)-(B). As noted, Plaintiff does not argue Mr. Frank’s benzene exposure and later development of ALL Leukemia are outside the definition of occupational disease under the current LWCA, thus the Court will assume they are covered for purposes of the present Motion. This assumption appears to be consistent with the jurisprudence. See e.g. Benoit v. Turner Indus. Grp., LLC,
. The Court assumes Plaintiff meant for this allegation to be in the negative form, that is that Shell did “not’' provide personal protective equipment.
. Although Plaintiff does not allege the type of insurance coverage provided by Travelers, if Travelers was Shell’s workers’ compensation insurer the result would be the same. See Gaylord Container/Temple Inland Corp. v. Dunaway, 2009-2058, pp. 4-5 (La.App. 1 Cir. 5/7/10),